Cytogenetic and clinical features of BCP-ALL with t(6;14)(p22;q32)
| Patient no. . | Trial . | Age, y/sex . | WBC ×109/L . | Karyotype* . | FISH . | EFS/OS, mo . | |||
|---|---|---|---|---|---|---|---|---|---|
| IGH@† . | IGH@-ID4 . | CDKN2A‡ . | PAX5§ . | ||||||
| 2125 | UKALLXI | 11/F | 3 | 47,XX,t(2;13)(p11;q1?),+5,t(6;14)(p22;q32),i(9)(q10)[cp5] | 1R1G1F (69%) | 1R1G2F (57%) | 0R2G0F (86%) | ND | 27/68¶ |
| 2817 | ALL97 | 14/M | 4 | 46,XY,i(9)(q10),t(6;14)(p22;q32)[8] | 1R1G1F (20%) | 1R1G2F (32%) | 1R2G0F (17%) | ND | 84+ |
| 3297 | ALL97 | 6/M | 6 | 46,X,-Y,der(4)t(4;9)(q2?;?),del(5)(q31), der(6)t(6;9)(p2?5;?),t(6;14)(p22;q32),add(9)(p2?), der(9)t(4;9)(q2?;p?)t(5;9)(q31;q22),-17,+22,add(22)(q?), der(22)t(10;22)(q11;q1?3),+mar,inc[cp3] | 1R1G1F (40%) | 2R1G1F (34%)‖ | 0R2G0F (32%) | 0R0G1F (32%) | 93+ |
| 3666 | UKALLXII | 45/M | 4 | 45,X,-Y,del(3)(q1?q2?9), der(6)del(6)(q1?3q?21)ins(6;3)(q1?3;q?q?) t(6;14)(p22;q32),i(9)(q10),add(12)(p13),1der(14)ins(14;12)(q32;?) t(6;14)(p22;q32),i(18)(q10)[cp7] | 1R1G1F (77%) | 1R1G2F (91%) | 1R2G0F (93%) | ND | 81+ |
| 3739 | ALL97 | 13/M | 5 | 46,XY,i(9)(q10),t(6;14)(p22;q32), del(17)(p11.1)[10]/47,idem,+5[2] | NA | NA | NA | NA | 66+ |
| 4341 | UKALLXII | 16/M | 1 | 48,XY,t(6;14)(p22;q32),+8,i(9)(q10),del(13)(q22q32),+22[7] | NA | NA | NA | NA | 66+ |
| 4767 | UKALLXII | 16/M | 11 | 46,XY,t(6;14)(p22;q32),i(9)(q10)[4] | NA | NA | NA | NA | 54+ |
| 6120 | MRD PILOT | 15/F | 2 | 47,XY,add(3)(q12),add(4)(q12),+5,+6,dic(6;9)(q1?5;p13), t(6;14)(p22;q32),i(9)(q10),add(10)(q22), der(10)t(4;10)(q21;q22),add(11)(p14)[13] | 1R1G1F (83%) | 1R1G2F (63%) | 0R2G0F (86%) | ND | 31+ |
| 7091 | UKALLXII | 34/F | 3 | 46,XX,-X,inv(1)(p1?q4?),add(4)(p?),+5,+del(5)(q2?), t(6;14)(p22;q32),dic(7;12)(p1?;p1?),add(8)(p?), der(9)t(X;9)(q1?3;p1?3),-13,+mar[cp6] | 1R1G1F (83%) | 1R1G2F (58%) | 1R2G0F (81%) | 0R0G1F (90%) | 2¶ |
| 7294 | ALL2003 | 15/M | 3 | 46–47,XY,add(3)(p2?6),del(3)(q2?5), +5,del(6)(q2?1),t(6;14)(p22;q32),inc[cp5] | 1R1G1F (28%) | 1R1G2F (58%) | 1R2G0F (59%) | 0R0G1F (31%) | NA |
| 12284 | ALL2003 | 19/F | 3 | 47,XX,t(6;14)(p22;q32),add(9)(p11),+mar[4] | 1R1G1F (65%) | 1R1G2F (65%) | 0R2G0F (40%) | 0R0G1F (64%) | NA |
| 11746 | UKALLXII | 48/M | 1 | 46,XY,t(6;14)(p22;q32),i(9)(q10),del(12)(p13),del(13)(q12q14)[16] | 1R1G1F (94%) | 1R1G2F (88%) | 1R2G0F (89%) | ND | NA |
| 16503 | ALL-BFM 2000 | 19/F | 3 | 45,XX,t(6;14)(p22;q32),i(9)(q10),del(13)(q12q33),-20[15] | 1R1G1F (82%) | 1R1G2F (88%) | 1R2G0F (74%) | ND | 30+ |
| Patient no. . | Trial . | Age, y/sex . | WBC ×109/L . | Karyotype* . | FISH . | EFS/OS, mo . | |||
|---|---|---|---|---|---|---|---|---|---|
| IGH@† . | IGH@-ID4 . | CDKN2A‡ . | PAX5§ . | ||||||
| 2125 | UKALLXI | 11/F | 3 | 47,XX,t(2;13)(p11;q1?),+5,t(6;14)(p22;q32),i(9)(q10)[cp5] | 1R1G1F (69%) | 1R1G2F (57%) | 0R2G0F (86%) | ND | 27/68¶ |
| 2817 | ALL97 | 14/M | 4 | 46,XY,i(9)(q10),t(6;14)(p22;q32)[8] | 1R1G1F (20%) | 1R1G2F (32%) | 1R2G0F (17%) | ND | 84+ |
| 3297 | ALL97 | 6/M | 6 | 46,X,-Y,der(4)t(4;9)(q2?;?),del(5)(q31), der(6)t(6;9)(p2?5;?),t(6;14)(p22;q32),add(9)(p2?), der(9)t(4;9)(q2?;p?)t(5;9)(q31;q22),-17,+22,add(22)(q?), der(22)t(10;22)(q11;q1?3),+mar,inc[cp3] | 1R1G1F (40%) | 2R1G1F (34%)‖ | 0R2G0F (32%) | 0R0G1F (32%) | 93+ |
| 3666 | UKALLXII | 45/M | 4 | 45,X,-Y,del(3)(q1?q2?9), der(6)del(6)(q1?3q?21)ins(6;3)(q1?3;q?q?) t(6;14)(p22;q32),i(9)(q10),add(12)(p13),1der(14)ins(14;12)(q32;?) t(6;14)(p22;q32),i(18)(q10)[cp7] | 1R1G1F (77%) | 1R1G2F (91%) | 1R2G0F (93%) | ND | 81+ |
| 3739 | ALL97 | 13/M | 5 | 46,XY,i(9)(q10),t(6;14)(p22;q32), del(17)(p11.1)[10]/47,idem,+5[2] | NA | NA | NA | NA | 66+ |
| 4341 | UKALLXII | 16/M | 1 | 48,XY,t(6;14)(p22;q32),+8,i(9)(q10),del(13)(q22q32),+22[7] | NA | NA | NA | NA | 66+ |
| 4767 | UKALLXII | 16/M | 11 | 46,XY,t(6;14)(p22;q32),i(9)(q10)[4] | NA | NA | NA | NA | 54+ |
| 6120 | MRD PILOT | 15/F | 2 | 47,XY,add(3)(q12),add(4)(q12),+5,+6,dic(6;9)(q1?5;p13), t(6;14)(p22;q32),i(9)(q10),add(10)(q22), der(10)t(4;10)(q21;q22),add(11)(p14)[13] | 1R1G1F (83%) | 1R1G2F (63%) | 0R2G0F (86%) | ND | 31+ |
| 7091 | UKALLXII | 34/F | 3 | 46,XX,-X,inv(1)(p1?q4?),add(4)(p?),+5,+del(5)(q2?), t(6;14)(p22;q32),dic(7;12)(p1?;p1?),add(8)(p?), der(9)t(X;9)(q1?3;p1?3),-13,+mar[cp6] | 1R1G1F (83%) | 1R1G2F (58%) | 1R2G0F (81%) | 0R0G1F (90%) | 2¶ |
| 7294 | ALL2003 | 15/M | 3 | 46–47,XY,add(3)(p2?6),del(3)(q2?5), +5,del(6)(q2?1),t(6;14)(p22;q32),inc[cp5] | 1R1G1F (28%) | 1R1G2F (58%) | 1R2G0F (59%) | 0R0G1F (31%) | NA |
| 12284 | ALL2003 | 19/F | 3 | 47,XX,t(6;14)(p22;q32),add(9)(p11),+mar[4] | 1R1G1F (65%) | 1R1G2F (65%) | 0R2G0F (40%) | 0R0G1F (64%) | NA |
| 11746 | UKALLXII | 48/M | 1 | 46,XY,t(6;14)(p22;q32),i(9)(q10),del(12)(p13),del(13)(q12q14)[16] | 1R1G1F (94%) | 1R1G2F (88%) | 1R2G0F (89%) | ND | NA |
| 16503 | ALL-BFM 2000 | 19/F | 3 | 45,XX,t(6;14)(p22;q32),i(9)(q10),del(13)(q12q33),-20[15] | 1R1G1F (82%) | 1R1G2F (88%) | 1R2G0F (74%) | ND | 30+ |
FISH data are genetic changes detected in the 4 genes shown, with percentage occurrence in parentheses.
R indicates red signal; G, green signal; F, fusion signal; EFS, event free survival; OS, overall survival; NA, not available; and ND, not done.
The normal clone has been omitted from the abnormal karyotypes.
1R1G1F indicates the presence of a translocation involving IGH@
0R2G0F and 1R2G0F indicate bi- and mono-allelic deletions, respectively, of CDKN2A.
0R0G1F indicates a monoallelic deletion of PAX5.
Patient has died.
This variant signal pattern was seen in interphase, the expected pattern (1R1G2F) was seen in metaphase with a faint IGH@ (G) signal present on the derived chromosome 14.